Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-AraG PET/MR Imaging of T-Cell Activation in Cancer Patients
NCT03007719Phase 2Terminated
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluorine f 18 ara-g in urothelial carcinoma (UC) and cancer (2 cohorts). Primary endpoint: Change Between Pre-treatment and Post-treatment SUVmax in Primary and/or Metastatic Tumors at 2 weeks. Started Mar 2017; status: terminated.
02
Drugs
fluorine f 18 ara-g
03
Conditions
urothelial carcinoma (UC)cancer
Beyond the preview
Go deeper on NCT03007719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007719.